World Health Organization recommends JAK inhibitor for treatment of severe or critical COVID-19

摘要

The World Health Organization (WHO) has “strongly recommended” baricitinib, a Janus kinase (JAK) inhibitor, for patients with severe or critical COVID-19. It has also issued a conditional recommendation for the use of sotrovimab, a monoclonal antibody, for the treatment of mild or moderate COVID-19 in high-risk patients. The recommendations, issued on 14 January 2021 (https://www.who.int/news/item/14-01-2022-who-recommends-two-new-drugs-to-treat-covid-19) , are based on evidence from seven trials involving more than 4,000 patients with a mixture of non-severe, severe and critical COVID-19. They form the eighth update of the WHO’s living guidelines on therapeutics and COVID-19.